Form 4 for REGN Regeneron Pharmaceuticals
Accepted 2021-12-23 00:00:00 ET · period of report 2021-12-22 · accession 0001883850-21-000034 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2021-12-23 | 2021-12-22 | REGN | YANCOPOULOS GEORGE | Pres, Chief Scientific, Dir | M - OptEx | $221.08 | +442.3K | 1.17M | +61% | +$97.78M |
| DM | 2021-12-23 | 2021-12-22 | REGN | YANCOPOULOS GEORGE | Pres, Chief Scientific, Dir | F - Tax | $610.04 | -310.1K | 1.02M | -23% | -$189.17M |
| DM | 2021-12-23 | 2021-12-22 | REGN | YANCOPOULOS GEORGE | Pres, Chief Scientific, Dir | M - OptEx | $0.00 | -442.3K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2021-12-22 | M | A | 239,063 | $179.13 | 1,126,546 | D | — | — | |
| 2 | Common | Common Stock | 2021-12-22 | F | D | 159,915 | $610.04 | 966,631 | D | — | — | |
| 3 | Common | Common Stock | 2021-12-22 | M | A | 203,204 | $270.43 | 1,169,835 | D | — | — | |
| 4 | Common | Common Stock | 2021-12-22 | F | D | 150,182 | $610.04 | 1,019,653 | D | — | — | |
| 5 | Derivative | Non-Qualified Stock Option (right to buy) | 2021-12-22 | M | D | 239,063 | $0.00 | 0 | D | $179.13 · — to 2022-12-14 | 239,063 Common Stock | (F2) The stock option award vests in four equal annual installments, commencing one year after the date of grant. |
| 6 | Derivative | Non-Qualified Stock Option (right to buy) | 2021-12-22 | M | D | 203,204 | $0.00 | 0 | D | $270.43 · — to 2023-12-13 | 203,204 Common Stock | (F2) The stock option award vests in four equal annual installments, commencing one year after the date of grant. |